Page 3 - Pharmacy

Election officer shuts Twenty20 pharma shop in Kerala for MCC violation

The District Election Officer (DEO) here on Monday directed the Twenty20 Association, linked with the Twenty20 political party run by business group Kitex, to shut down a recently opened medical shop offering substantial discounts, for violating the Model Code of Conduct (MCC). The district collector, who is also the returning officer, pointed out that the private company, the registered association and the political party all share the same logo and the same set of executives. The order came on a complaint filed by two residents, that the medical shop opened next to the Bhakshya Suraksha Market, run by the Kizhakkambalam Grama Panchayat ruled by the Twenty20 party, was in violation of the MCC. "Prima facie, it is revealed that there is a violation of section 4.4.2B(i) of the manual on MCC, and there is a case here which may influence the voters in freely exercising their right to vote by inducement through gratification," the order read. The DEO said, "It is a unique case where th

Best of BS opinion: Simultaneous elections, pharma regulation & more

Here is the best of Business Standard's opinion pieces for today

Indian firms corner more of growing pharma market as MNCs go niche

Indian drug firms are focussing on expanding their salesforce and distri­bution, while getting into trade generics to garner volumes

Cipla forges strategic partnership for global cell therapy advancements

The collaborative effort is aimed at developing and commercialising novel Cell therapy products for critical unmet medical needs in the US, Japan, and the EU

Investor perception about Aster DM Healthcare is 'very upbeat': CEO

Group will avoid being 'one of those players' with a token presence through a single hospital, says Nitish Shetty

CM Patnaik approves hike in monthly stipend of nursing, pharmacy students

Odisha Chief Minister Naveen Patnaik on Wednesday approved a hike in the stipend amount for students of nursing, pharmacy and other related categories, officials said. The move followed a request by the students in this regard, they said. Students of Diploma in Pharmacy students will now get Rs 500 per month from the earlier amount of Rs 250, ANM Rs 2,000 from Rs 1,000, B.Sc (Nursing) internship course Rs 5,000 from Rs 2,500, M. Phil in Clinical Psychology and M.Phil in Psychiatric Social Work Rs 10,000 from Rs 7,000, an official release said. The decision was made taking into account the importance of services being rendered by them, it said.

Pharma industry optimistic, expects more collaborative efforts in New Year

The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership. The industry, known for catering to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research & Development (R&D) and uphold quality standards to meet the evolving healthcare needs. "The convergence of policy thrust, and India's entrepreneurial vigour will propel the sector's growth and ensure a consistent supply of quality-assured affordable medicines for patients, both in India and globally," Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain told PTI. IPA comprises top domestic pharmaceutical companies, including Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma, Cipla, Lupin and Glenmark. Jain said that this year, the government announced various policy initiatives like the Promotion of Research .

NCB-Mumbai busts international pharma-drugs trafficking syndicate; 3 held

The apprehended accused have been identified as V Singh, G Mishra, and P Sharma, added the official statement

Dr Reddy's becomes 1st Indian pharma firm on Dow Jones Sustainability index

Dr. Reddy's Laboratories Ltd on Thursday said it has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance (ESG) agenda. Dr. Reddy's has become the first Indian pharma company to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023, a press release from the drug maker said. Alongside its debut in DJSI World, the company retains its place in the Dow Jones Sustainability Index for Emerging Markets (DJSI EM) for the eighth year in a row based on Dr. Reddy's performance in the Standard & Poor Global Corporate Sustainability Assessment (S&P Global CSA) and additional screening criteria. Separately, Dr. Reddy's has been awarded Gold Medal' status by EcoVadis, the global sustainability ratings agency, for its score of 70 out of 100 in its scorecard for 2023. G V Prasad, Co-Chairman & Managing Director, Dr. Reddy's, said: As a company with over two decades of ...

Hospital and pharmacy chain Aster to fuel India expansion through buyouts

Aster plans to add an additional 1,500 beds to the current 4,800 capacity in the world's most populous country over the next three years and "look at companies that are not listed

Aster DM Healthcare sells stake in Gulf business for $1.01 billion

Aster to separate its India and GCC businesses to unlock value

Health Ministry seeks public comments on draft Pharmacy Commission Bill

The new pharmacy commission will be headquartered in New Delhi and shall consist of a Chairperson, thirteen ex-officio and fourteen part-time members

Lupin receives approval from the US FDA for its Selexipag for injection

In 2022, sales of the Selexipag Franchise in the US stood at $ 1.1 billion. The sales for January 1 to September 30, 2023, stood at $978 million

Aster DM Healthcare's India unit draws suitors valuing business at $1.5 bn

Aster shares have soared about 40% this year, valuing the Mumbai-listed company at about $1.9 billion

Stride Pharma Global receives USFDA approval or Efavirenz, other drugs

The company aims to launch about 60 new products in the next three years in the US market

Missouri's CVS pharmacists plan more walkouts over working conditions

After the walkouts began Thursday, the chain dispatched Chief Pharmacy Officer Prem Shah to meet Tuesday with the pharmacists

World Pharmacists Day 2023: Date, theme, history, importance and more

World Pharmacists Day is observed globally every year on September 25th. It serves to respect and value the contribution of pharmacists in improving global health

Occupancy surge, pharmacy profitability key triggers for Apollo Hospitals

As compared to 64% in the March quarter, overall occupancies across hospitals in the group were at 62%

LS passes bill to recognise pharmacists qualified under J-K Pharmacy Act

The Lok Sabha on Monday passed a bill allowing persons qualified or registered under the Jammu and Kashmir Pharmacy Act to be registered as pharmacists under the Pharmacy Act, thus doing away with the ambiguity with regard to the two legislations. Piloting the Pharmacy (Amendment) Bill, 2023, Health Minister Mansukh Mandaviya said that changes will increase job opportunities for the youth of Jammu and Kashmir. The bill, which was passed by voice vote in the Lower House, seeks to do away with issues concerning the status of persons registered or qualified under the Jammu and Kashmir Pharmacy Act. Under the current dispensation, registration under the Pharmacy Act is mandatory for persons practising pharmacy in the country. "Any person whose name has been entered in the register of pharmacists maintained under the Jammu and Kashmir Pharmacy Act, 2011, or possesses qualification (medical assistant/ pharmacists)... shall be deemed to have been entered in the register of pharmacists ...

Bulk drug imports from China hit 75% in FY23 despite PLI scheme: Report

Bulk drug imports from China increased from 62 per cent to 75 per cent in the past nine years and India continues to depend on Chinese shipments despite commissioning of various domestic manufacturing projects under the government's production-linked incentive scheme, a report said. According to a report by Care Ratings, imports of bulk drug from China have soared in terms of both value as well as volume from 64 and 62 per cent in FY14 to 71 and 75 per cent in FY23, respectively. In value terms, during FY14 to FY23, the country's total bulk drug imports from China increased at a compounded annual growth rate of about 7 per cent, indicating that the country continues to rely heavily on its northern neighbour for some of the critical key starting materials (KSMs), said Ranjan Sharma, a senior director with Care Ratings. In FY14, the country imported a total of USD 5.2 billion of pharma, of which as much as USD 2.1 billion came in from China. The numbers rose to USD 6.4 billion and USD